Germany · Health startup

Emperra

Emperra GmbH E-Health Technologies is a German company located in Potsdam, specializing in digital health solutions for diabetes management.

Funding reportedLast round: Equity crowdfunding

HealthPotsdam, Germany

About Emperra

Emperra GmbH E-Health Technologies is a German company located in Potsdam, specializing in digital health solutions for diabetes management.

The company is led by Dr. med. Janko Schildt and is registered at Amtsgericht Potsdam. Emperra focuses on e-health technologies, particularly in telemedicine for optimizing metabolic health in diabetes care. The main product offered by Emperra is ESYSTA, a digital health application that includes the ESYSTA portal and app. This system is designed for self-management and monitoring of diabetes mellitus treatment, supporting both type 1 and type 2 diabetes patients who use insulin. ESYSTA features automatic wireless tele-monitoring with smart insulin pens, enabling outpatient care and facilitating telemedicine support from healthcare providers to enhance metabolic control.

What company datasets say Emperra raised

Funding, as reported

Reported in all7.3Min the source's currency
Rounds3
Last roundEquity crowdfunding
Last round size3.1M
Last round dateMay 2020
Investors listed9

On a portfolio page

Investors who name them

Each firm lists Emperra on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

The company, in detail

What they build

Known for

health careremote monitoringdigital healthdiga applicationpatient self-managementehealthcomputer & network securitymedical device softwareinformation technology & servicestelemedicinedata securityiso/iec 27001medizintechnikhospital & health caremedicalb2c

Sector
Health
Industry code
NAICS 33911, 334510, 513210, SIC 3845, 3841, 7372
Region
Brandenburg
Full record
Every detail in the company directory

Health in Germany

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Emperra in front of investors. Or tell us what we have wrong.